Financial PerformanceFull-year 2023 financial results reported a net loss greater than anticipated, with a revised full-year 2024 net loss estimate due to higher operating expenses.
Regulatory IssuesThe FDA issued a clinical hold on the IND submission for Entrada's lead candidate, ENTR-601-44, and the nature of the hold hasn't been disclosed.
Regulatory IssuesENTR-601-44 remains on clinical hold in the U.S. following communication from the FDA.